Compare Amylx Pharmaceuticals Inc (AMLX) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Thomson Reuters Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.26 (market cap $1.98B), while Thomson Reuters Corp trades at $93.63 (market cap $38.95B). The key difference: Thomson Reuters Corp is far larger — about 19.7× Amylx Pharmaceuticals Inc's market cap, and Thomson Reuters Corp pays a 2.92% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | TRI | |
|---|---|---|
Market Cap | $1.98B | $38.95B |
Sector | Health | Industrials |
52-Week High | $18.70 | $214.21 |
52-Week Low | $7.64 | $76.55 |
Enterprise Value | $1.70B | $40.91B |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Thomson Reuters (TRI) trades at $89.65, up 0.92% today, with a bullish technical signal and strong support at $88. The company shows robust fundamentals with a 19.93% net income margin and consistent earnings beats, though Q4 2025 missed expectations. Recent AI partnerships and a special dividend highlight strategic moves, while cash flow turned negative in 2025 due to investing activities.
Outlook is positive with a consensus price target of $129.96, implying 45% upside, supported by 51.85% analyst buy ratings. Risks include AI implementation challenges and revenue volatility, but the stock's valuation at P/E 25.8 appears reasonable given growth prospects in legal and compliance sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
